Kepler Capital Thinks Genfit SA’s Stock is Going to Recover
In a report issued on June 8, David Evans from Kepler Capital maintained a Buy rating on Genfit SA (GNFT), with a price target of EUR7.50. The company’s shares closed last Wednesday at $4.14, close to its 52-week low of $3.63.
According to TipRanks.com, Evans is a 4-star analyst with an average return of 8.7% and a 67.3% success rate. Evans covers the Healthcare sector, focusing on stocks such as Quantum Genomics, Innate Pharma, and Crossject SA.
Currently, the analyst consensus on Genfit SA is a Moderate Buy with an average price target of $10.71.
See today’s analyst top recommended stocks >>
Genfit SA’s market cap is currently $190.8M and has a P/E ratio of -1.30. The company has a Price to Book ratio of -9.06.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company focuses on the discovery and development of drug candidates in areas of high unmet medical needs corresponding to a lack of suitable treatments. It focuses on medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver. The company was founded by Jean-François Mouney, Florence Séjourné and Bart Staels on September 1999 and is headquartered in Loos, France.